PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer

The aim of this study was to explore the efficacy of mTOR inhibitor for castration-resistant prostate cancer (CRPC) under hypoxia. Although under normoxia C4-2AT6, it is a CRPC cell line, expressed elevated pAkt, pS6 and Pyruvate kinase M2 (PKM2) accompanied by elevated HIF-1a expression, 5% hypoxic...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Yasumizu, Yota, Hongo, Hiroshi, Kosaka, Takeo, Mikami, Shuji, Nishimoto, Koshiro, Kikuchi, Eiji, Oya, Mototsugu
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021245/
https://ncbi.nlm.nih.gov/pubmed/29963230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25498
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items